ANCC Review Questions (PMHNP IQ) and Answers 2025

ANCC Review Questions (PMHNP IQ) and
Answers 2025
WhatAdirect-actingAdopamineAreceptorAagonistAisArecommendedAtoAbeAusedAinAtheA
treatmentsAofAneurolepticAmalignantAsyndromeA(NMS)AfoAhelpAlowerAtheAdopamineA
blockade?

A)AbenzotropineA(Cogentin)
B)AbromocriptineA(Parlodel)
C)AdantroleneA(Dantrium)
D)AtrihexyphenidylA(Artane)A-ACORRECTAANSWERSA-
A)ABromocriptineA(Parlodel)AisAtheArecommendedAdirectAactingAdopamineAreceptorAagonis
tAtoAhelpAdecreaseAtheAdopamineAblockade.ADanroleneA(Dantrium)AisAaAmuscleArelaxant.A
BenzotropineA(Cogentin)AandATrihexyphenidylA(Artane)AareAanticholinergicAmedicationsAu
sedAforAextrapyramidalAsideAeffectsA(EPS).
Mr.ASmithAisAaA56AyearAoldAwhiteAmaleAwhoAhasAbeenAsuccessfullyAtreatedAonASelegilineAf
orAoverA4Ayears.AMr.ASmithAisAgoingAinAforAelectiveAsurgicalAprocedure.AWhichAmedicationAi
sAstrictlyAcontraindicatedAwithASelegiline?

A)ANon-steroidalAanti-inflammatoryAdrugsA(NSAIDS)
B)ACodeine
C)AMorphine
D)AMeperidineA-ACORRECTAANSWERSA-
D)AMeperidineAisAstrictlyAprohibitedAwhenAaApatientAisAtreatedAonAaAmonoamineAoxidaseAin
hibitorA(MAOI)AdueAtoAtheAriskAofAhypertensiveAcrisisAandAdeath.
AAWBCAofA4,000AinAaApatientAtakingAClozapineAwouldApromptAtheAPMHNPAtoAtakeAwhichAo
fAtheAfollowingAactions?

A)AConsultAwithAhematologistAtoAdetermineAappropriateAantibioticAregimenAandAmonitorAcl
osely.
B)AInstituteAtwice-weeklyAcompleteAbloodAcountAwithAdifferentialsAandAmonitorAclosely.
C)ADiscontinueAclozapine,AinitiateAalternativeAantipsychoticAmedicationAandAmonitorAclosel
y.
D)AInstituteAdailyAcompleteAbloodAcountAwithAdifferentialsAandAmonitorAclosely.A-
ACORRECTAANSWERSA-B)AInstituteAtwice-

weeklyAcompleteAbloodAcountAwithAdifferentialsAandAmonitorAclosely.A

TheArecommendedAcut-
pointsAforAdiscontinuationAofAclozapineAareAWBCAofA2,000AtoA3,000AorAgranulocytesAofA1,0
00AtoA1,500AforAagranulocytosisAandAseverelyAcompromisedAimmuneAsystem.AAtAaAWBCAo
fA4,000,AtheArecommendationAisAtoAcloselyAmonitorACBCAwithAdifferentialAtwiceAaAweekAwhi
leApatientAmayAcontinueAclozapineAinAtheAabsenceAofAanyAotherAsignsAorAsymptoms.

, AApatientAwithAaAdiagnosisAofAschizophreniaAhasAaAhistoryAofAsuicidalAideationAandAsuicideA
attempts.ATheAPMHNPAshouldAconsiderAwhichAantipsychoticAmedicationAthatAisAtheAonlyAa
ntipsychoticAtoAreduceAtheAriskAofAsuicideAinAschizophrenia?

A)AAbilifyA(aripriprazole)
B)ALatudaA(lurasidone)
C)AInvegaA(iloperidone)
D)AClozarilA(clozapine)A-ACORRECTAANSWERSA-
D)AClozarilA(clozapine)AisAtheAonlyAknownAantipsychoticAmedicationAthatAhadAbeenAshownA
toAreduceAtheAriskAofAsuicideAinApatientsAdiagnosedAwithAschizophrenia.
AApatientAbeingAtreatedAforAmajorAdepressiveAdisorderAandAonAsertralineA(Zoloft),A150AmgA
poAdailyAforAtheApastA16Ayears,ApresentsAtoAtheApsychiatricAmentalAhealthApractitionerAforAa
nAoutpatientAfollow-
upAvisit.ADuringAtheAvisitAsheAstatesAthatAsheAhasAnotAbeenAfeelingAwell,AreportingAtheAflu.AS
heAalsoAstatesAsheAhasAnotAtakenAherAmedicationAinAtheAlastAfiveAdays.AWhichAofAtheAfollow
ingAsymptomsAwouldAsheAbeAdescribingAifAyouAsuspectAselectiveAserotoninAreputableAinhib
itorsA(SSRIs)AdiscontinuationAsyndrome?

A)AAgitation,Anausea,Adysphoria,AandAdiequilibrium
B)AAgitation,Anausea,Atremor,AandAataxia.
C)ARestlessness,Atremor,Afever,AandAshivering.
D)ARestlessness,Aheadache,AincreasedAheartArate,AandAdiarrhea.A-
ACORRECTAANSWERSA-A)AAgitation;Anausea,Adysphoria,AandAdisequilibrium




TheApatientAhasASSRIAdiscontinuationAsyndromeAandAwouldAbeApresentingAwithAflu-
likeAsymptoms.AIfAtheApatientAhadAserotoninAsyndrome,AsheAwouldApresentAwithAsymptoms
AofAautonomicAinstability.

WhichAofAtheAfollowingAstatementsAreflectAtheAcurrentAunderstandingAofAdopamineA(DA)Ap
athwaysAandAclinicalAsymptomsAinAschizophrenia?

A)ANegativeAsymptomsAareArelatedAtoADAAdeficitAinAtheAcerebralAcortex;ApositiveAsymptom
sAareArelatedAtoADAAexcessAinAtheAnucleusAaccumbensAandAmesolimbicAsystem.

B)ANegativeAsymptomsAareArelatedAtoADAAexcessAinAtheAcerebralAcortex;ApositiveAsympto
msAareArelatedAtoADAAdeficitAinAtheAnucleusAaccumbensAandAmesolimbicAsystem.

C)ANegativeAsymptomsAareArelatedAtoADAAexcessAinAtheAmesolimbicAsystem;ApositiveAsym
ptomsAareArelatedAtoADAAdeficitAinAtheAsubstantiaAnigraAandAventralAtegmentalAarea.
NegativeAsymptomsAareArelatedAtoADAAdeficitAinAtheAmesolimbicAsystem;ApositiveAsympto
msAareArelatedAtoADAAexcessAinAtheAsubstantiaAnigraAandAventralAtegmentalAarea.A-
ACORRECTAANSWERSA-

A)ANegativeAsymptomsAareArelatedAtoADAAdeficitAinAtheAcerebralAcortex;ApositiveAsymptom
sAareArelatedAtoADAAexcessAinAtheAnucleusAaccumbensAandAmesolimbicAsystem.

NegativeAsymptomsA&AcognitiveAimpairmentAareAthoughtAtoAbeArelatedAtoAhypoactivityAofAt
heAmesocorticalAdopiminergicAtract,AwhichAbyAitsAassociationAwithAtheAprefrontalAcortexAan